ClearPath Strategies

ClearPath Strategies offers strategic consulting, campaign expertise, and public opinion research for the world's game-changing leaders and progressive forces. Our work spans more than 60 countries across six continents, ClearPath offers a combination of research and consulting solutions tailored to our clients' diverse backgrounds and diverse challenges. Whether it is winning elections, strengthening corporate reputation and positioning, understanding consumer insights, carving out a thought-leadership role, or implementing complicated and innovative research, anywhere, the one thing our clients have in common is the need for a clear strategy based on insightful research. OUR MISSION ClearPath's mission is to promote the game-changing leaders and progressive forces around the world who tirelessly strive to make life better for more people. We believe that the future belongs to bold, innovative, and responsive leaders, who carry out pragmatic solutions for people's problems. ClearPath provides these leaders with world-class research, deep campaign experience, cutting-edge technologies, and creative executions for how to engage with people. Working in partnership with these leaders and their teams, ClearPath delivers winning solutions to move them, their causes, their companies forward. They make it their mission to help make life better for people. We make it our mission to put them in position to succeed.

ATDBio (now part of Biotage)

We design and synthesise complex oligonucleotides the way you need them; pure and simple. Our world-leading R&D expertise is the foundation of our approach. We listen, discuss and support scientist-to-scientist – using our chemical insight to identify where we can make the biggest difference to your project. Our deep understanding of oligonucleotide chemistry enables us to choose optimal methods for incorporating unusual functionalities. And, most importantly, it means that we supply you with the purest products in the best possible yields. At each stage we take pride in finding the simplest, most practical solutions, backed up by rigorous analysis. It's key to your success, and it's at the heart of our transparent production process.

Nantes Institute for Advanced Study

Nantes Institute for Advanced Study brings together researchers and intellectuals from every continent. They all have in common the fact that they consider the diversity of thought systems as an indispensable support to the institution of reason in a world destined to remain diverse and unpredictable. It is modeled on the inspiration of Princeton, where carefully selected researchers are able to benefit from temporary freedom from scheduling, teaching and administrative commitments to devote themselves to the advancement of fundamental knowledge, notably pushing back disciplinary, institutional and cultural boundaries. The IAS-Nantes was officially recognized as being of public utility. It entered the prestigious consortium SIAS (Some Institutes for Advanced Study) in 2015 alongside the 8 other leading IAS throughout the world: Princeton, Stanford, Harvard, North Carolina, Berlin, Uppsala, Wassenaar and Jerusalem.

DIACCURATE

Endocrine-resistant metastatic breast tumor, glioblastoma, refractory acute myeloid leukemia, … to beat incurable cancers, Diaccurate explores the new frontiers of oncology in search of daring novel therapeutic approaches able to save lives. Now in the clinic, the French biotech is currently developing 3 proprietary therapeutics with novel mechanisms of action across several development programs: - DIACC3010, an optimized S6 Kinase inhibitor, highly selective oral antitumoral agent that crosses the blood-brain barrier - DIACC2010, a sole-in-class KIF20A kinesin inhibitor, a novel oncology target, IV antitumoral agent with high selectivity towards cancer cells -DIACC2020, antibody drug conjugate using DIACC2010 as payload Co-founded by Truffle Capital, Diaccurate has forged alliances with leaders in academia and industry, including Pasteur Institute, Paoli-Calmettes Institute (Marseille, France) and now Merck KGaA (Darmstadt, Germany). It relies on a high-level management team led by Dominique Bridon, PhD and a world-class Scientific Advisory Board chaired by Prof. Tasuku Honjo, recipient of the 2018 Nobel Prize in Medicine.

CRBio-02

EXERCÍCIO LEGAL DA PROFISSÃO, CONFORME PREVÊ A LEI 6684, DE 03/09/1979 Somente se registram nos Conselhos Regionais de Biologia os portadores de diploma de bacharel ou licenciatura em curso de História Natural ou de Ciências Biológicas, em todas as suas especialidades ou de licenciatura em Ciências com habilitação em Biologia, expedido por instituição brasileira oficialmente reconhecida ou por instituições estrangeiras de ensino superior, regularizado na forma da lei, cujos cursos forem considerados equivalentes aos mencionados no inciso I, Art. 1º da Lei nº 6684 de 03 de setembro de 1979. Para o exercício das atividades de Biólogo previstas no Art. 2 da Lei nº 6684, em qualquer modalidade de relação trabalhista ou empregatícia, será exigido, como condição essencial, a apresentação da Carteira Profissional emitida pelos regionais. O Sistema CFBio/CRBios registra os graduados que se formaram em cursos presencias e à distância.